Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.67 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | PPARD | Q03181 | 6/20 | 0.47 |
| ▸ | PPARA | Q07869 | 6/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL5605357 | 1.00 | SLC7A5 (0.67) | SLC7A5S1PR2S1PR1S1PR3ALPI | |
| Stearic Acid SCHEMBL4276901 | 1.00 | SLC7A5 (0.67) | SLC7A5S1PR2S1PR1S1PR3ALPI | |
| Tyrosine SCHEMBL27434350 | 0.93 | SLC7A5 (0.77) | SLC7A5ALPIPKMPTGS1XIAP | |
| Tyrosine SCHEMBL27703156 | 0.93 | SLC7A5 (0.77) | SLC7A5ALPIPKMPTGS1XIAP | |
| Oleic Acid SCHEMBL28343224 | 0.93 | SLC7A5 (0.57) | SLC7A5PTGS1PPARGPPARDPPARA | |
| Palmitic Acid SCHEMBL466917 | 0.93 | SLC7A5 (0.57) | SLC7A5S1PR2S1PR1S1PR3ALPI | |
| Decanoic Acid SCHEMBL17667545 | 0.89 | ALPI (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL598090 | 0.89 | ALPI (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dodecanoate SCHEMBL599337 | 0.89 | ALPI (0.65) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL598091 | 0.89 | ALPI (0.65) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115192706-B | Preparation method of novel gold nanoparticle and application of novel gold nanoparticle in tumor treatment | 中国医学科学院肿瘤医院 | 2023-05-26 | — | — | CN | disclosed |
| CN-115192706-A | Preparation method of novel gold nanoparticles and application of novel gold nanoparticles in tumor treatment | 中国医学科学院肿瘤医院 | 2022-10-18 | — | — | CN | disclosed |
| EP-1948199-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LAB INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1960415-B1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LAB INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8293253-B2 | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LABORATORIES, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8114440-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8017159-B2 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LABORATORIES, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100204303-A1 | Pharmaceutical Compositions for Administering Oligonucleotides | IDEXX LABORATORIES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-7754679-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1960415-A2 | PHOSPHOLIPID GEL COMPOSITIONS FOR DELIVERY OF APTAMERS AND METHODS OF TREATING CONDITIONS USING SAME | IDEXX Laboratories Inc (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1948199-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX Laboratories Inc (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1804771-A2 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | IDEXX LABORATORIES, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007058800-A2 | PHOSPHOLIPID GEL COMPOSITIONS FOR DELIVERY OF APTAMERS AND METHODS OF TREATING CONDITIONS USING SAME | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058801-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070110775-A1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2006050002-A2 | COMPOSITIONS FOR CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | IDEXX LABORATORIES, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060093632-A1 | Compositions for controlled delivery of pharmaceutically active compounds | IDEXX LABORATORIES, INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093632-A1 | Compositions for controlled delivery of pharmaceutically active compounds | LIPA, CEL, LPXN | SLC7A5 1567/4885S1PR2 1725/4885S1PR1 1569/4885 |
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | PHOSPHO1, SGMS1, PCYT1A | SLC7A5 228/4885S1PR2 29/4885S1PR1 38/4885 |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | SLC7A5 228/4885S1PR2 29/4885S1PR1 38/4885 |
| US-20100204303-A1 | Pharmaceutical Compositions for Administering Oligonucleotides | SLCO2A1, SLCO1A2, SLCO2B1 | SLC7A5 16/4885S1PR2 754/4885S1PR1 977/4885 |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | SLC7A5 228/4885S1PR2 29/4885S1PR1 38/4885 |
| US-20070110775-A1 | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | ANXA6, ANXA2, PLTP | SLC7A5 2133/4885S1PR2 96/4885S1PR1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.